Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. [electronic resource]
Producer: 20000210Description: 889-94 p. digitalISSN:- 0959-4973
- Adult
- Aged
- Agranulocytosis -- chemically induced
- Antineoplastic Agents -- adverse effects
- Area Under Curve
- Female
- Humans
- Indoles -- adverse effects
- Infusions, Intravenous
- Male
- Maximum Tolerated Dose
- Middle Aged
- Nausea -- chemically induced
- Neoplasms -- drug therapy
- Pyridines -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.